Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial.

The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic non-small cell lung cancer without EGFR, ALK, or ROS1 mutations.

The results showed sustained survival benefits, with patients receiving Libtayo plus chemotherapy showing a 19.4% chance of survival at five years. The survival rate is notable, as it is more than double the 8.8% survival rate of chemotherapy alone. Moreover, the safety remained consistent with earlier reports. The results reinforce Libtayo plus chemotherapy as an effective first-line treatment option for advanced NSCLC.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.